Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:22:09.687Z.
Calculation as of: 2026-10-06T17:22:09.687Z.
Quote observation: 2026-10-06T17:19:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$139.73M
Price/FCF Ratio
1.11
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$142.01M
Price/FCF Ratio
N/A
TTM Avg
34.10
3Y Avg
34.10
5Y Avg
34.10
Market Cap
$142.56M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.95M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$137.11M
Price/FCF Ratio
520.40
TTM Avg
1083.05
3Y Avg
1083.05
5Y Avg
1083.05
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $140.67M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 1.11 | 4.90 | 4.90 | 4.90 |
| Sutro Biopharma, Inc. (STRO)vs › | $142.01M | N/A | 34.10 | 34.10 | 34.10 |
| Protara Therapeutics, Inc. (TARA)vs › | $142.56M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $138.69M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $143.95M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $144.10M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.11M | 520.40 | 1083.05 | 1083.05 | 1083.05 |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.82M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $135.38M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
